State of the art progress of Evolvulus alsinoides in pharmacological activity and plant tissue culture: A potent Chinese medicinal plant by Collince Omondi Awere, Valentine Chikaodili Anadebe, Rakkammal Kasinathan, Pandiyan Muthuramalingam, Ramesh Manikandan

“…Nevertheless, thorough clinical trials and translational research are required to bridge the gap between conventional knowledge and current medical uses. …”
Get full text

ZBiotics ameliorates T2DM-induced histopathological damage in liver, kidney and adipose tissues by modulating the NOD-like receptor signaling in Wistar rats by Mohammed Esawie, Marwa Matboli, Mariam Sameh Bushra, Amany H. Hasanin, Eman Kamal Habib, Reham Hussein Mohamed, Hebatalla Said Ali

“…ZBiotics is recommended for clinical trials as a separate candidate or as an adjuvant to the conventional T2DM therapy.…”
Get full text

Daratumumab for autoimmune diseases: a systematic review by Martin Krusche, Ina Kötter, Lennard Ostendorf, Nikolas Ruffer, Marie-Therese Holzer, Tobias B. Huber

“…Therefore, systematic clinical trials of this therapeutic approach are needed.…”
Get full text

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review by Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek

“…Gastric emptying and insulin secretion are also affected by GLP-1 RAs. Clinical trials consistently demonstrate significant weight loss, positive action on cardiovascular risk and better glycemic control. …”
Get full text

The REpeated ASSEssment of SurvivorS in intracerebral haemorrhage: protocol for a multicentre, prospective observational study by Daniel Woo, Richard Thompson, Carl D Langefeld, Nichol McBee, Daniel Hanley, Matthew L Flaherty, Lauren Sansing, Karen Lane, Lee A Gilkerson, Achala Vagal, Nathan Walborn, Wendy Ziai, Noeleen Ostapkovich, Kevin Triene, Timothy David Howard

“…The findings of the study will be published in academic peer-reviewed journals.Trial registration number NCT05611918; ClinicalTrials.gov; registered on 23 May 2023.…”
Get full text

No Effect of Return to Sport Test Batteries with and without Psychological PROs on the Risk of a Second ACL Injury: A Critical Assessment of Four Different Test Batteries by Ramana Piussi, Rebecca Simonson, Johan Högberg, Roland Thomeé, Kristian Samuelsson, Eric Hamrin Senorski

“…There is a need for clinical trials to integrate psychological patient-reported outcomes (PROs) in return to sport batteries assessing patients treated with ACL reconstruction…”
Get full text

The Taking Charge After Stroke (TaCAS) study protocol: a multicentre, investigator-blinded, randomised controlled trial comparing the effect of a single Take Charge session, two Ta... by Mark Weatherall, Harry McNaughton, Vivian Wai Yin Fu

“…Results will be published and presented at relevant stroke meetings within New Zealand and internationally, informing the use of a self-management intervention after stroke.Trial registration Australia and New Zealand Clinical Trials Registry ACTRN12615001163594. Date registered 02-11-2015. …”
Get full text

Evaluation of a Low-threshold Exercise And Protein supplementation intervention for Women (LEAP-W) experiencing homelessness and addiction: Protocol for a single-arm mixed methods... by Fiona Kennedy, Deirdre Murray, Clíona Ní Cheallaigh, Roman Romero-Ortuno, Julie Broderick

“…The findings of this research will help narrow the research gap and will guide clinicians and policy makers to implement unique gender-based treatment strategies for this population. (300).<h4>Clinical trials.gov number</h4>NCT05700305.…”
Get full text

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia by Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock

“…**Background:** Research has shown that treatment interruptions are associated with worse failure-free survival in chronic myeloid leukemia (CML); however they are commonly used in clinical trials to manage adverse events. **Objectives:** This study assessed the comparative rates of treatment interruption and regimen change between patients initiating first-line therapy with a first-generation tyrosine kinase inhibitor (1GTKI) imatinib versus second-generation TKI (2GTKI), dasatinib or nilotinib, for the treatment of CML in clinical practice. …”
Get full text

Beliefs about HIV cure: A qualitative study of people living with HIV in Soweto, South Africa by Fatima Laher, Naledi Mahlangu, Mbalenhle Sibiya

“…Background: Rare cases of HIV cure exist. Clinical trials of HIV cure are also underway. However, little is documented about how potential cures are perceived by African people living with HIV, although they are key stakeholders. …”
Get full text

Measles neutralising antibody levels in patients receiving intravenous immunoglobulin treatment - a sub-analysis of a randomized, cross-over bioequivalence trial. by Vatsala Rajendram, Martyn Paddick, John More

“…<h4>Trial registration</h4>ClinicalTrials.gov NCT01963143.…”
Get full text

Acupoint stimulation for postpartum breastfeeding insufficiency: a systematic review and meta-analysis by Ya-Ching Chang, Yi-An Wang, Zi-Yu Chang, Jian-An Liao

“…Methods A systematic search of seven databases (PubMed, MEDLINE, Embase, Cochrane, CNKI, Airiti Library, ClinicalTrials.gov) was performed from their inception dates to September 30, 2023. …”
Get full text

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary by Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

“…**Background:** Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of PEG and RBV in treatment of patients chronically infected with genotype 1 hepatitis C virus (HCV) infection. …”
Get full text

Therapeutic strategies for fungating and ulcerating breast cancers: A systematic review and narrative synthesis by Valentina Zagardo, Mandara Harikar, Gianluca Ferini

Get full text

Nebulised 3% hypertonic saline versus 0.9% saline for treating patients hospitalised with acute bronchiolitis: protocol for a randomised, double-blind, multicentre trial by Sara Szupieńko, Aleksandra Buczek, Henryk Szymański

“…The findings of the study will be submitted to a peer-reviewed journal, and abstracts will be submitted to relevant national and international conferences.Trial registration number ClinicalTrials.gov Registry (NCT06069336).…”
Get full text

Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database by Tomohiro Iida, Aya Narimatsu, Kenji Adachi, Edward CY Wang

“…**Conclusion:** In a real-world setting in Japan, anti-VEGF PRN injections are administered less frequently than in clinical trials, and with time between monitoring and re-injection visits. …”
Get full text

Pain Assessment Following Open Hemorrhoidectomy Under Local Anesthesia Versus Saddle Block: A Multicenter Randomized Controlled Trial. by Sikakulya, Franck Katembo, Ssebuufu, Robinson, Okedi, Xaviour Francis, Baluku, Moris, Lule, Herman, Kiyaka, Sonye Magugu, Kyamanywa, Patrick

“…Trial registration Pan African Clinical Trials Registry, PACTR202110667430356. Registered on 8th October, 2021.…”
Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

“…Methods: This phase 1, open-label, dose-finding study evaluated the maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics of ESK-440 in participants with advanced or metastatic solid tumors (ClinicalTrials.gov: NCT01922752). A 3 + 3 dose-escalation design, with daily doses ranging from 25 to 700 mg/day of ESK-440 for each 28-day treatment cycle (6 to 8 cycles) was utilized to identify the MTD. …”
Get full text

A comprehensive review on the plant sources, pharmacological activities and pharmacokinetic characteristics of Syringaresinol by Lei Zhang, Yuqing Tian, Lingling Zhang, Huanyu Zhang, Jinghua Yang, Yi Wang, Na Lu, Wei Guo, Liang Wang

“…Moreover, no thorough comprehensive summary and evaluation of Syringaresinol has been conducted to offer recommendations for potential future clinical trials and therapeutic applications of this bioactive compound. …”
Get full text

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma by Hui-Ju Hsieh, Ryan Urak, Mary C. Clark, Larry W. Kwak, Stephen J. Forman, Xiuli Wang

“…However, pan-AKT inhibitors have been applied against cancers with PIK3CA/AKT/PTEN alterations in clinical trials. We evaluated ex vivo and in vivo strategies of enhancing CAR T cell therapeutic effect using the pan-AKT inhibitor capivasertib. …”
Get full text